Analysis
Roche has neutralized the direct financial impact of U.S. reciprocal tariffs through a comprehensive three-year contract finalized with the U.S. government. Under this agreement, the company is granted a full exemption from tariffs—including the 10% base rate and higher country-specific levies introduced in April 2025—for the 2026-2028 period. In exchange for this status, Roche has committed to multi-billion dollar domestic investments and pricing concessions, effectively trading tariff costs for localized growth and expanded access.
The primary cost of this exemption is a commitment to invest $50B in the United States over the next five years. This capital is allocated toward R&D and manufacturing capacity at key sites, including Genentech in San Francisco, a research hub in Boston, and major manufacturing facilities in North Carolina and Indianapolis. Additionally, Roche agreed to provide Medicaid rebates on select products within its portfolio and to support direct-to-patient medication access for its influenza franchise, including Xofluza and Tamiflu.
Prior to securing this exemption, Roche experienced modest financial headwinds. The Diagnostics division recorded a CHF 64M tariff-related cost during the second half of 2025. To mitigate broader supply chain risks during the initial implementation of the April 2025 tariffs, Roche proactively shifted CHF 2.2B in inventory and net trade working capital. This front-loading strategy was designed to bridge operations until the formal government contract could be established and localized production could be scaled.
Management maintains that its long-term strategy of localized manufacturing in major markets acts as a structural hedge against trade volatility. By balancing imports and exports within the U.S., Roche aims to maintain a neutral tariff position independent of future administrative changes. The company’s increased donations to independent co-pay assistance foundations—which doubled in 2025—further align with its strategy to maintain patient access and volume growth despite the pricing pressures inherent in its federal trade agreement.
Data
($M, except as noted)
| Impact Category | Metric | FY 2025 |
|---|---|---|
| Direct Tariff Cost | Diagnostics Segment Headwind | (64.0) |
| Supply Chain Mitigation | Inventory/Working Capital Shift | (2,200.0) |
| Mitigation Commitment | 5-Year U.S. Investment ($B) | $50.0B |
Source: Transcript FY-2025, Transcript 1Q-2025, Marvin Labs
Financial Impact
- Cost Impact (Historic): CHF64M
Sources
The agreement we reached with the US government is not an LOI; it's a contract with the U.S. government. And based on this contract... we get an exemption from tariffs... for the next three years.
We had the situation that we had to deal with the tariffs. So we brought inventories up a little bit... that contributed to the CHF 2.2bn net trade working capital movement.
Last but not least, we had a tariff impact on the diagnostic side of CHF 64 million half-year impact. So that's also something we potentially have to deal with in 2026.